Penumbra, Inc. (PEN) Earnings Call Transcript & Summary

May 7, 2020

New York Stock Exchange US Health Care Health Care Equipment and Supplies earnings 44 min

Earnings Call Speaker Segments

Jee Hamlyn-Harris

executive
#1

Thanks, operator, and I appreciate everyone being here today as we go over Penumbra's results for Q1 2020. You can find the press release along with the financial tables — including the GAAP to non-GAAP reconciliation — under the Investors tab at www.penumbrainc.com. On this conference call, we'll be making forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, covering things like our financial performance, commercialization efforts, clinical trials, regulatory status, quality, compliance, and business trends. Actual results may differ materially from what's stated or implied in those forward-looking statements because of various risks and uncertainties, such as those referenced in our 10-Q for the quarter concluded March 31, 2020, set to be filed with the SEC on May 7, 2020, and those outlined in our 10-K for the year concluded December 31, 2019, filed with the SEC on February 26, 2020. So we urge you not to place undue reliance on these forward-looking statements, and we encourage you to look at our periodic SEC filings, including the previously mentioned 10-Q and 10-K, for a fuller discussion of these factors and other risks that could impact our future results or the market price of our stock, including but not limited to how the COVID-19 pandemic affects our business, results of operations, and financial condition. Penumbra undertakes no duty to update or revise our forward-looking statements because of new information, future events, developments, or otherwise. Some financial measures on this call are presented on a non-GAAP basis. A reconciliation of GAAP to non-GAAP financial measures appears in our posted press release; we expect the prepared comments today will take about 18 minutes. Adam Elsesser, Penumbra's Chairman and CEO, will give a business update. Maggie Yuen, our Chief Financial Officer, will then go over our financial results for the quarter; and Sri Kosaraju, our President, will offer concluding remarks. With that, I'd like to hand the call over to Adam Elsesser.

Adam Elsesser

executive
#2

Thank you, Jee. Good afternoon, and thanks for being with us on Penumbra's First Quarter 2020 Conference Call. We're going to run today's earnings call in a different format than our previous ones, so that we can speak not only to our quarterly performance but also to the bigger issues related to the COVID-19 pandemic. That pandemic has already had, and will keep having, a major effect on global society, health and the economy. Penumbra has dealt with difficult periods in the past, but clearly nothing like this has ever come our way. Even so, when conditions get tough, the mission and culture we've built over the years have served as important compass points, and we believe they will continue to guide us through this extraordinary period. Starting in early March, we acted swiftly on several fronts in light of the pandemic. The first of those efforts was aimed at protecting the physical health and financial well-being of our employees and their families. After that, we turned our attention to ensuring we could keep supplying and standing behind our customers, suppliers and business partners — all of which allowed us to fulfill our top priority, which is serving patients. It's our shared hope that this pandemic will be over before long and that we'll be able to return to a more typical working situation. Even so, the changes we've made allow Penumbra to keep running in this new, safer way for as long as necessary, and they also allow us to resume this mode of operation should further waves of the pandemic hit. That's why we feel very confident about carrying out our mission for the duration of this pandemic. Here's how our specific company actions break down into strategic priorities: number one, reorganizing our manufacturing operations so that our employees stay protected throughout the pandemic; number two, strengthening a balance sheet that was already solid; and number three, putting Penumbra in a position to come out of the pandemic in even better shape. To kick things off, I want to walk through our Q1 performance and touch on some early signals we picked up in April. After that, I'll shift to the bigger question of how we plan to steer this company successfully through the pandemic and position ourselves to emerge strong once it's behind us. On the Q1 numbers: consolidated revenue came in at $137.3 million, which represents growth of 6.9% compared with the same period last year on a reported basis, or 7.6% when you strip out currency effects. If you set Japan aside, our constant currency figure rose 14.3% year over year, and it was essentially level on a sequential basis relative to the fourth quarter. During the quarter, our operating income came in at $0.6 million, whereas for the equivalent period a year ago, it was $11.2 million. Maggie is going to walk through the financials in more depth, covering a few extra period expenses we absorbed this quarter, and in her remarks she'll also give you specifics about our balance sheet. As we moved into the first quarter, we started seeing business trends take a hit from COVID-19, especially during March. I'd like to pass along a few things we've noticed across our business up through the close of — through the month of April. Even though we're just at the beginning of this pandemic, some signs that things may be stabilizing have started to show up. That said, it's worth emphasizing these reflect what we're seeing right now, and things could shift quickly depending on various factors both in the United States and across the globe; the way revenues have fallen relative to normal pre-COVID patterns has differed depending on geography, the kind of procedure, and the channel. From a geographic standpoint, the earliest hit to our business appeared in COVID-19 hotspots, before spreading more widely as communities took proactive steps toward strict physical distancing. On a global basis, during April, average daily sales trends across our direct geographies dropped roughly 35% against pre-COVID levels. Here in the United States and in Europe, April sales ran about 30% below pre-COVID levels. Just to clarify, the percentage changes we're talking about are measured against recent patterns from the three months before COVID. They are not year-over-year comparisons. In terms of procedure type, Neuro has generally held up better for us; in both the U.S. and Europe, average daily sales during April were down about 20% to 25% versus pre-COVID levels. Turning now to Vascular: we saw a drop of about 35% compared with pre-COVID trends. Vascular procedures are more often elective in nature, and the data we've gathered indicates that the volume of urgent cases showing up at hospitals is significantly below normal. Over the past several weeks, numerous physicians have told us they're encountering more COVID-19 patients with large vessel thrombosis, which leads to DVT, PE and lower extremity arterial occlusions; it's too soon for that to meaningfully appear in our numbers, but it's an emerging phenomenon we're monitoring very closely. Finally, when we consider many of our international distributor channels, especially in China and Japan, we think a lagging effect tied to COVID-19 will surface, and so we'd anticipate that showing up in Q2 ordering patterns. Let me shift my commentary now to spotlight a handful of favorable operational and pipeline developments from the quarter before COVID-19's impact. In January, we held a ceremony to cut the ribbon at a new production site in Roseville, California. Eventually, this site will allow us to produce more than three times what we can manufacture today. For now, however, it gives us a large amount of additional room to grow our manufacturing output while maintaining physical distancing rules that keep our employees safe. Late in February and early in March, we received two notable FDA clearance announcements — one from Neuro and one from Vascular. Each of these regulatory approvals came through faster than expected, but we will adjust our schedule for bringing these new technologies to market to whenever it makes sense to involve our physician customers. Having this extra time gives us a chance to sharpen our commercial approaches so they work better in the current climate. As for the first quarter, the last thing to mention is that we want to recognize and praise how remarkably the whole Penumbra team has handled the problems and hurdles tied to COVID-19 from early March onward. They have demonstrated the character, resilience and ability needed to guide the company through such a tough stretch. There are plenty of examples of outstanding work taking place. Still, I believe everyone at Penumbra would share the view that it makes sense to single out the tremendous efforts of our production and operations teams. Beyond reorganizing the way we manufacture, inspect and ship products so that all our employees stay as safe as possible, we ran into yet another obstacle in mid-March. Right as we were embarking on this new path, a 5.7 magnitude earthquake struck the Salt Lake City area, where a warehouse holding substantial inventory is located. Both our people and the inventory came through safely, yet it required tremendous effort and sacrifice from a California team and the Salt Lake City team to get the warehouse operating normally again within 24 hours. That heroic work meant little to no interruption in our capacity to deliver our critical products to those who need them.

Adam Elsesser

executive
#3

At this point, I want to spend a short while discussing the strategic priorities I laid out earlier. The way we manufacture, examine and deliver our products has been completely reorganized, with our employees' health and safety coming first; what that means is that we're running under the physical distancing rules and other safety requirements set by local and state government orders; we've managed to implement significant adjustments that let us do this while, up to now, meeting product demand. On top of that, our commercial team has told our customers that we're ready to stand behind them whenever they need us. Beyond that, though, we've stayed out of their way while they deal with the numerous urgent problems that health care professionals face these days. We've also acted to safeguard and strengthen a balance sheet that was already solid. We hold roughly $170 million in cash and carry no debt. On top of that, our team moved fast to establish a $100 million revolving line of credit together with JPMorgan, Bank of America and Citibank. Our view is that this is a sensible step to provide us with extra capital access as we steer through today's conditions. Last, we're setting ourselves up to come out of this pandemic even stronger within a new environment. That effort includes simplifying certain workflow and decision-making along with some functions, in recognition of the remarkable young leadership that has come forward in this period. We've also rethought the way our commercial teams will and ought to engage with customers moving forward, which lets us remain supportive and useful while accounting for the new paradigm. In addition, we've kept putting money into key opportunities. As an example, we've sped up development programs for the REAL System to pursue fresh opportunities arising straight out of this pandemic. We'll continue seeking internal and external opportunities that are vital and needed to assist patients through this difficult period. To close my remarks today, I'd like to point out that in a once-in-a-lifetime crisis, both individuals and companies will be judged on our attitude, our readiness to assist and our compassion toward others. It makes me proud to say that each person at Penumbra has met this moment's challenge, and working alongside them is an honor. We wish to convey our genuine admiration and respect for our health care workers, first responders and other workers in essential businesses who labor so hard to keep everyone safe and healthy. And above all, everyone at Penumbra wants to remember and grieve the loss of so many people across the United States and throughout the world. Their families and communities are in our thoughts. I'll now hand the call over to Maggie.

Maggie Yuen

executive
#4

Thanks, Adam. Good afternoon to all of you, and I hope you and your families are staying safe and healthy. For the first quarter, which ended March 31, 2020, total revenues came in at $137.3 million — that's up 6.9% as reported and up 7.6% on a constant currency basis versus the first quarter of 2019. Looking at the geographic split of sales for the quarter, 70% came from the U.S. and 30% was international. Neuro accounted for 57% of sales and Vascular accounted for 43%. Our Vascular business brought in $59.3 million of revenue during the first quarter of 2020, which represents growth of 26.2% as reported and 26.5% in constant currency. Growth in Vascular during the quarter was fueled by results from both our thrombectomy business and our embolization business. Revenue from our Neuro business reached $78.1 million in the first quarter of 2020, which was down 4.2% as reported and down 3.3% in constant currency against the same period a year ago. If we exclude Japan, our Neuro business was up 5.1% versus the first quarter of 2019 and flat versus the fourth quarter of 2019. The performance of our Neuro business was mainly driven by sales of a Penumbra system for ischemic stroke. Gross margin for the quarter stood at 64.1% of revenues, compared with 65.3% of revenues in the same quarter last year. Before COVID-19, our production capacity, efficiency and productivity had been improving consistently throughout the last 12 months. Our margin performance in the first quarter of 2020 reflects volume deleveraging, with only a minimal impact from average selling price and product mix. During the quarter, we kept overall manufacturing spending at the same levels as the fourth quarter of 2019, because we made a deliberate choice to keep paying all of our direct labor at 100% while lowering labor capacity per shift in order to achieve social distancing and employee safety measures. Because of this, certain labor costs showed up as additional period expense in the quarter. The reduction in labor capacity was offset by overall productivity, which allowed us to support demand. For the second quarter, we expect our gross margin to be lower as a result of volume absorption. Total operating expense for the quarter was $87.4 million, or 63.6% of revenue, versus $72.8 million, or 56.6% of revenue, in the same quarter a year ago. In the first quarter of 2020, our operating expense reflects a limited reduction tied to activities restricted by COVID-19, such as travel and entertainment expenses; over the near term, there will be some natural reduction in expense related to the current environment. We've also put other cost control measures in place; for instance, as we mentioned in our preannouncement, more than 20 senior executives have voluntarily taken a substantial temporary salary reduction. While we remain disciplined about controlling spend, we will also keep prioritizing our investment in our production capacity, commercial channels, new product launches and new product development. Our research and development expenses were $12.9 million for the first quarter of 2020, compared with $11.7 million for the first quarter of 2019. For the first quarter of 2020, SG&A came in at $74.5 million, versus $61.1 million during the same quarter in 2019. Operating income for the quarter was $0.6 million, compared with $11.2 million of operating income in last year's comparable period. Now let's move on to cash flow and the balance sheet. As of the close of first quarter 2020, we held $168 million across cash, cash equivalents and marketable securities, with no debt on the books. Cash usage during the quarter totaled $20 million, which is above what we typically see. That cash consumption was mainly tied to inventory build-up, locking in material supply, capital investment tied to new product launches and the ordinary timing of some cash outlays. To further shore up our liquidity position, on April 24 we completed a $100 million revolving credit facility alongside JPMorgan, Bank of America and Citigroup. Beyond the company's already solid net cash position, this revolving line of credit gives us even more access to capital, which lets us both steer through the present environment and act on opportunities. At this point I'd like to hand the call over to Sri for closing remarks.

Sridhar Kosaraju

executive
#5

Thanks, Maggie. Just like Adam said earlier, Penumbra has weathered tough periods before. Our mission has guided where we're headed, and our culture has driven the team to deliver so we can safeguard both our employees and our stakeholders. Even though we're likely still at an early stage of this pandemic, signs of stabilization have begun to appear. Within just a few weeks, we've managed to evaluate how the near term will hit our business and to pursue major measures aimed at sharpening how we operate and strengthening our balance sheet. Those initial moves matter and are essential if we're going to make the correct long-term calls for the business. Moments like these define any organization, and I have no doubt that Penumbra stands as well positioned as any company to come out of this crisis stronger. I'd also like to express my appreciation to each Penumbra employee for the sacrifices all of you are making right now. And my thanks go out as well to the thousands of health care professionals and first responders whose efforts let us stay safe and do what we do every day. Thanks. At this point we'd like to take your questions. Operator, please go ahead.

Bob Marcus

analyst
#6

Let me just kick things off. It honestly strikes me as remarkable that even your Neuro revenue dropped by that much during Q2. For me, that suggests people are passing away at home from strokes instead of being admitted to hospitals. So I'd like to know if you could discuss a few of the patterns you're observing in that area. Also, was this mostly an April phenomenon, when ICUs were — and ORs were overwhelmed by COVID patients? Or do you believe this could drag on further, as patients would rather avoid a hospital than receive care?

Adam Elsesser

executive
#7

Yeah. Robbie, this is Adam. That's a completely fair question. I believe there are several distinct kinds of developments, clearly, taking place in hospital systems everywhere — not just across the United States but globally too. One phenomenon has to do with what's occurring within the hospital walls. Clearly, with stroke and several other conditions regarded as critical, there's been considerable media attention on patients avoiding hospitals, and this has appeared both in recent press coverage and in scientific journals. Be it heart attacks, strokes, or other critical problems, there's a period, especially acutely during late March and through April, when those figures fell dramatically. So I believe that explains a great deal of it — people felt worried or fearful about entering hospitals. The presumption is that they wished to avoid catching the virus by going there. We don't know precisely why, but that's the assumption. And that likely accounts for most of it. Hospitals, as you're aware, are — and we've verified this with several of our customers and, well, hospitals that they're reconsidering how they'll function moving forward in any case. There's a strong feeling that this won't be finished at any point soon. And they'll reorganize the way they approach and care for patients and ensure that within their communities, the message gets out that they can be a safe destination to visit. Certain hospitals, as you know, and this is purely anecdotal, are discussing separate entrances on one side of the building versus the other for COVID patients versus those with non-COVID conditions, plus physical barriers inside the hospital so those zones stay segregated. And I think those are the sorts of changes that we'll witness as — how communities respond to those matters shifts. And once more, we're already observing that over the past week or 2, somewhat encouraging movement in that direction. So I think we hold some optimism that critically ill patients will feel at ease entering most hospitals in the future.

Bob Marcus

analyst
#8

And on the other side of things, maybe with Peripheral, Indigo prevents patients from needing ICUs, and it allows them to open up capacity and have patients exit the hospital more quickly. So I realize it's difficult right now to go out and sell physical products inside the hospital, but do you see this as an inflection point that might drive broader uptake of Indigo for these patients?

Adam Elsesser

executive
#9

Yeah. That's a great question. I believe Indigo has several compelling aspects here. In a way — at the most basic level, there's no question that's correct. Infusing tPA generally means entering the ICU and closely watching those patients, as opposed to simply taking out clot, which was among the foundational ideas behind the product. I do believe — and I highlighted this in the prepared remarks, specifically regarding Indigo — that the decline in cases stems partly from the same thing I just discussed, which is people not arriving at the hospital in the first place. So it isn't a matter of them arriving and then being placed in an ICU; it's that they never arrive at all. I think another piece adds to that, where we're observing — and you're seeing this once more in the recent press, there were a few articles about it, especially concerning younger stroke patients lately — that there's this occurrence of hypercoagulability emerging in these patients or taking place, which is a terrible extra kind of condition or tragedy to inflict on these patients, yet one that physicians want to figure out how to tackle and handle some of those problems. The most awful part is that you don't — you aren't succumbing to the usual respiratory problems, but instead you wind up dying from a PE brought on by the virus. So we actually hosted, not a product-specific kind of webinar recently but about a week ago, a cross-disciplinary webinar focused on just how you treat these patients with these sorts of large thrombus burdens that they've developed; we had more than 400 registered physicians sort of calling in to listen, since it's a truly growing problem; and we've observed a bit of an uptick in those figures over the last week or so, which gives us some indication that they're being cared for properly. Also, in contrast to an ordinary product, for which demand could vary, as you're aware, we have a distinctly approved Indigo item—one that received clearance prior to these events and which remains unlaunched. I hinted at our capacity to devise and create the appropriate format and approach for doing so within this fresh context and model. My belief is that considerable curiosity and demand will exist for it, especially at present, considering what we've just discussed—things that might benefit doctors and those they treat, including individuals with COVID at this moment. That provides us with a genuine purpose regarding this during the coming quarter or 2.

Larry Biegelsen

analyst
#10

I've got just a couple. The first concerns the new products, the second is about Japan. So, Adam, you received approvals for 2 significant new products recently. I realize you aren't rolling them out right away given the coronavirus situation. Still, I'd love to know what's incremental, what's novel and distinctive regarding these 2 offerings — JET 7, XTRA FLEX, MAX in Neuro, plus Indigo with Lightning. Then I have a follow-up.

Adam Elsesser

executive
#11

Thanks, Larry, for that question. On this call, I won't get into the particular technical enhancements and specifics concerning those products, and I hope and trust — I hope you understand my reasoning. We'll hold off until we're set to share that with the physician community. That said, especially regarding the Indigo side — and this isn't meant to diminish the stroke product — the Indigo one, in my view, could discover a notably welcoming audience, considering what I mentioned when answering Robbie's most recent question. I believe it will essentially make those procedures quicker, more efficient, and more thorough; and at a moment such as this, especially with COVID patients facing some of these problems, it will represent a significant addition to what we offer. You had a question — a second one?

Larry Biegelsen

analyst
#12

That helps. Yeah, I did. Regarding Japan, it appears the country declined roughly $7.5 million versus the prior year during Q1. What's your outlook for how that unfolds across the remainder of 2020? From what I recall, Japan represented $43 million for you folks in 2019. My understanding is you anticipated a drop of roughly $24 million compared with the previous year, around that figure, at the time guidance was given. So whatever fresh information you have would be useful.

Sridhar Kosaraju

executive
#13

Larry, this is Sri. I'll handle that question. Concerning Japan, clearly, given the COVID-19 pandemic, we are monitoring the situation carefully; that is, clearly, the main piece of new information since our previous call, a status update on it. We intend to keep a close watch. In my view, the quarter unfolded as we had anticipated based on our prior call and what you mentioned, and that remains our expectation, though clearly with the significant caveat posed by the COVID-19 pandemic.

Matt Henriksson

analyst
#14

Matt Henriksson here, filling in for Joanne. Our first question concerns REAL and the stroke rehabilitation centers. In what ways are they adjusting to the current COVID-19 situation? Specifically, how much of the work with these patients can happen via telemedicine, and what portion still demands visits to the center?

Adam Elsesser

executive
#15

Excellent question — happy to take that one. There are actually a number of distinct settings, or venues, where we had anticipated and designed the REAL system to benefit patients: beginning with acute centers, the hospitals where they receive treatment, then moving into what's more like a standard inpatient rehab stay, and finally transitioning to outpatient rehab afterward. The first 2 of those remain applicable. Those patients in such facilities are definitely still receiving treatment. The counts might be a bit lower, as we noted regarding stroke, yet they remain in acute centers, and they're also definitely in inpatient clinics, and in those places they are being treated. Launching a product amid all this is tough — going into those centers and holding those conversations. So instead of the usual approach, we're exploring a different method — rather than the standard process we kicked off at the start of the year for rolling the product out and how we went about it. I believe we can share a bit more specifics on that shortly. With that said, outpatient facilities are truly quite different. A lot of them have shut down and simply aren't positioned to keep operating the way they did previously, whether because of physical distancing rules or mandates, or merely apprehension about doing so. There's been some talk and a shift toward something closer to a tele-rehab style of model — though pulling that off well is difficult. You're essentially relying on phone calls, FaceTime, or meetings to motivate someone to perform tasks that are challenging even when you're physically present with them; and there's clearly an opportunity, which I referenced in my prepared remarks, to substantially enhance and tackle some of those gaps that this awful pandemic has created. So keep watching for further information as it comes out. Still, I'd say the underlying need exists, and I think some fresh opportunities have arisen.

Matt Henriksson

analyst
#16

No; that's really helpful context. Now for my next question. You mentioned that worldwide same-day sales figures were roughly 35% lower compared with the sort of levels seen before COVID. I just want to make sure whether that figure takes into account the effect in Japan stemming from the reimbursement modification.

Sridhar Kosaraju

executive
#17

Yes. That's an excellent question for clarification. We had stated direct in order to sort of make that distinction. Clearly, the same-day sales differ when distributors are involved. They aren't really daily; therefore, that mirrors what you'd call direct worldwide sales.

Margaret Kaczor

analyst
#18

For my first question, maybe you could just spend a bit of time discussing market development work and what your approach was for that through the pandemic and honestly in the quarters after it. So which sorts of steps or partnerships might you pursue to shift toward a virtual education platform for Peripheral, as an example? And then a comparable question about virtual sales, since sales have likely transformed not just right now but moving forward with essential employees and hospitals and so forth.

Adam Elsesser

executive
#19

Yes. Thank you. That's a great question. Clearly, virtual technology gives us ways to engage with people, whether in bigger or smaller gatherings — along with the more predictable examples, such as a webinar that pulled in a solid number of attendees on a subject closely tied to this crisis. One account also came out involving a doctor at a hospital: Indigo was already being used there, brought in by a different physician, though this particular doctor had not used it before. A COVID-19 patient of theirs had a really significant clot burden, which ultimately resulted in a PE, and via FaceTime alone — unless I'm remembering wrong — our sales rep was basically able to train them from a distance and be present to help with that case. Once again, the whole thing started with the doctor getting in touch and asking our team to provide support, and the outcome for that patient turned out to be truly satisfying and exceptional. So there will be — and indeed there already are — opportunities to stand behind the physician community through this period. You can look at it and wonder, "How much longer is this going to last?" In what ways does this alter the very nature of our interactions?" While I won't lay out every aspect of what we intend to do, what I can say is that we're genuinely—I'd say—thrilled. What excites me is that this opens the door for us to build far less hands-on approaches, in contrast to how we've historically run things, the way nearly all med tech firms operate, which tends to be quite hands-on. You walk into the hospital. You sit down with your customers. You discuss your offerings with them. You move through that kind of workflow. That's exactly what we witnessed happening across our Vascular business over the past several years. Getting that done isn't quick, and my sense is we can speed things up by taking a less heavy-handed approach — one that cuts down on how much direct, hands-on involvement is needed. Once the timing makes sense, and once there's genuine demand and appetite for it, we'll begin demonstrating that and putting those ideas to the test. My guess is the earliest instance will coincide with the initial rollout of the upcoming Indigo offering.

Margaret Kaczor

analyst
#20

All right, that's useful. This next one is somewhat related, also about reporting clinicians, but the situation is different now because of the pandemic. A lot of these people are under operational strain, and companies are beginning to discuss ways to assist them — not just with the patients they already treat, but with running their businesses in ways they might not have considered, since they aren't business people. So could you give us a sense of what you're doing at this moment to get them through this period that might set you apart from some competitors?

Adam Elsesser

executive
#21

Sure. I'm not entirely clear on the question regarding what we're doing to assist the hospitals directly. Of course, we'll do whatever we can to back them up. We — at times, our products get used in situations where we're supplying inventory. There are specific instances needing additional inventory or similar things. We can keep doing that when asked. So we've built the ability to handle that in a possibly wider manner, especially as we learn more about elective procedures being scheduled and the requirement for particular moments of inventory rather than having overall par levels go up in cost-effective ways. The team here has built, in my view, substantial ability to back that up. Again, our willingness to be present and answer requests rather than adopting more of a sales posture and attempting to persuade them to use our product has been very positively received by — throughout the Board from our customer base. That's basically our main focus at present; though I believe once they emerge from this, they'll begin performing more elective procedures, and it truly comes down to being there to — first, with inventory; and second, with expertise if they want it.

Jee Hamlyn-Harris

executive
#22

Appreciate it, operator. From everyone on our leadership group, thanks once more for being with us right now and for the attention you're giving Penumbra. We're eager to bring you the latest during our call for the second quarter.

Operator

operator
#23

This concludes today's conference call. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Penumbra, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Penumbra, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Penumbra, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.